BR112015008663A2 - proteínas imunomodulatórias - Google Patents

proteínas imunomodulatórias

Info

Publication number
BR112015008663A2
BR112015008663A2 BR112015008663A BR112015008663A BR112015008663A2 BR 112015008663 A2 BR112015008663 A2 BR 112015008663A2 BR 112015008663 A BR112015008663 A BR 112015008663A BR 112015008663 A BR112015008663 A BR 112015008663A BR 112015008663 A2 BR112015008663 A2 BR 112015008663A2
Authority
BR
Brazil
Prior art keywords
immunoglobulin
heavy chain
chain constant
mammalian subject
polypeptide monomer
Prior art date
Application number
BR112015008663A
Other languages
English (en)
Other versions
BR112015008663B1 (pt
Inventor
John Pleass Richard
Original Assignee
Liverpool School Tropical Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47216360&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015008663(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liverpool School Tropical Medicine filed Critical Liverpool School Tropical Medicine
Publication of BR112015008663A2 publication Critical patent/BR112015008663A2/pt
Publication of BR112015008663B1 publication Critical patent/BR112015008663B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Abstract

resumo da patente de invenção para: “proteínas imunomodulatórias”. a presente invenção se refere a um método para tratamento de um sujeito mamífero para uma doença autoimune ou inflamatória, o método compreendendo: a administração a um sujeito mamífero de uma quantidade eficaz de uma proteína polimérica compreendendo cinco, seis ou sete unidades de monômero de polipeptídeo; em que cada unidade de monômero de polipeptídeo compreende uma porção de ligação ao receptor fc compreendendo duas regiões constante de cadeia pesada da imunoglobulinas g; em que cada região constante de cadeia pesada da imunoglobulina g compreende um resíduo de cisteína que está ligado através de uma ligação dissulfeto a um resíduo de cisteína de uma região constante de cadeia pesada de uma imunoglobulina g de uma unidade de monômero de polipeptídeo adjacente; em que a proteína polimérica não compreende uma porção imunomoduladora adicional; ou uma porção do antígeno que causa imunossupressão antígeno-específica, quando administrado ao sujeito mamífero
BR112015008663-2A 2012-10-17 2012-10-17 Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo BR112015008663B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2012/052561 WO2014060712A1 (en) 2012-10-17 2012-10-17 Immunomodulatory proteins

Publications (2)

Publication Number Publication Date
BR112015008663A2 true BR112015008663A2 (pt) 2017-09-26
BR112015008663B1 BR112015008663B1 (pt) 2021-01-12

Family

ID=47216360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008663-2A BR112015008663B1 (pt) 2012-10-17 2012-10-17 Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo

Country Status (9)

Country Link
US (3) US20150218236A1 (pt)
EP (1) EP2908914B1 (pt)
JP (1) JP2015536317A (pt)
CN (2) CN104870055A (pt)
AU (1) AU2012392760C1 (pt)
BR (1) BR112015008663B1 (pt)
CA (1) CA2888519C (pt)
RU (1) RU2015118063A (pt)
WO (1) WO2014060712A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132364A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
EP3131926A1 (en) * 2014-04-16 2017-02-22 UCB Biopharma SPRL Multimeric fc proteins
BR112016024780A2 (pt) * 2014-05-02 2017-10-10 Momenta Pharmaceutical Inc composições e métodos relacionados com construtos de fc manipulados
WO2016154118A1 (en) 2015-03-20 2016-09-29 The Rockefeller University Immune complex
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201515745D0 (en) * 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins
BR112018014668A2 (pt) * 2016-01-27 2018-12-11 Csl Behring Recombinant Facility Ag multímeros de fc de igg recombinante
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
JP7075100B2 (ja) 2016-03-30 2022-05-25 エービー バイオサイエンシーズ， インコーポレイテッド 組換え静注用免疫グロブリン（ｒＩＶＩＧ）組成物ならびにその製造及び使用方法
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
EP3484514B1 (en) 2016-05-23 2023-12-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
EP3487534A4 (en) 2016-07-22 2020-03-25 Gliknik Inc. FUSION PROTEINS FROM HUMAN PROTEIN FRAGMENTS FOR THE PRODUCTION OF MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH INCREASED FC RECEPTOR BINDING
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
CA3049383A1 (en) 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
WO2019115745A1 (en) 2017-12-14 2019-06-20 CSL Behring Lengnau AG RECOMBINANT igG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
GB2572008A (en) * 2018-03-16 2019-09-18 Liverpool School Tropical Medicine Murine antibodies
CA3115547A1 (en) * 2018-11-14 2020-05-22 Jn Biosciences Llc Multimeric hybrid fc proteins for replacement of ivig
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
CA3159705A1 (en) 2019-12-06 2021-06-10 CSL Behring Lengnau AG Stable compositions of fc multimers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082137A4 (en) 1998-05-06 2004-05-19 Univ Temple REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007332085A1 (en) * 2006-12-13 2008-06-19 Suppremol Gmbh Multimeric Fc receptor polypeptides including a modified Fc domain
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
RU2549676C2 (ru) * 2007-06-01 2015-04-27 Юниверсити Оф Мэрилэнд, Балтимор СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР
US20100023966A1 (en) 2008-07-22 2010-01-28 At&T Labs System and method for contextual adaptive advertising
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
CN103154036B (zh) * 2010-07-28 2016-05-11 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物

Also Published As

Publication number Publication date
JP2015536317A (ja) 2015-12-21
US20180086797A1 (en) 2018-03-29
WO2014060712A1 (en) 2014-04-24
AU2012392760C1 (en) 2021-08-12
EP2908914A1 (en) 2015-08-26
CN110894231A (zh) 2020-03-20
AU2012392760B2 (en) 2018-06-28
EP2908914B1 (en) 2018-04-18
US20180362600A1 (en) 2018-12-20
US20150218236A1 (en) 2015-08-06
CN104870055A (zh) 2015-08-26
CA2888519A1 (en) 2014-04-24
CA2888519C (en) 2023-02-21
BR112015008663B1 (pt) 2021-01-12
AU2012392760A1 (en) 2015-05-07
RU2015118063A (ru) 2016-12-10

Similar Documents

Publication Publication Date Title
BR112015008663A2 (pt) proteínas imunomodulatórias
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EA201791057A1 (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf
BR112017015287A2 (pt) anticorpos para fcrn e métodos de uso dos mesmos
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
BR112017009264A2 (pt) proteína de ligação a epítopo ou um fragmento da mesma e imunoglobulina heterodimérica ou um fragmento da mesma
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
AR086693A1 (es) PROTEINAS HUMANAS DE UNION AL ANTIGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE b-KLOTHO Y UN RECEPTOR PARA FGF
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
NZ719654A (en) Interleukin-2 fusion proteins and uses thereof
PH12016500943A1 (en) Aplnr modulatros and uses thereof
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
PE20150023A1 (es) Proteinas de union a antigeno st2
BR112015000798A2 (pt) heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
BR112017023646A2 (pt) proteínas agonistas de receptor de cd40 de cadeia simples
BR112013028523A8 (pt) Uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte
BR112017020915A2 (pt) ?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
MA34004B1 (fr) Protéines de liaison à cd127

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: CSL BEHRING LENGNAU AG. (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI 2590 DE 25/08/2020.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/10/2012, OBSERVADAS AS CONDICOES LEGAIS.